On July 17, 2026, a clinical trial update was recorded for a study involving desmopressin, an approved compound. The trial, registered as NCT07712328, is titled "Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors."
The study is listed as Phase 4 and its current status is enrolling by invitation. This designation means the trial is recruiting participants who have been specifically selected or referred, rather than through open public enrollment.
The trial focuses on the prophylactic intraoperative use of desmopressin in patients with complex sellar region tumors, according to the registered title. No results, efficacy outcomes, or safety findings have been reported as part of this update. The listing reflects only the trial's design, phase, and enrollment status as of the date provided.
Further details about the study protocol, eligibility criteria, and objectives can be found through the official trial registration. As the trial progresses, additional updates may become available regarding its status or outcomes.
Readers interested in learning more about desmopressin can refer to the compound overview for additional context.